BRPI0612833A2 - composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras - Google Patents

composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras Download PDF

Info

Publication number
BRPI0612833A2
BRPI0612833A2 BRPI0612833-5A BRPI0612833A BRPI0612833A2 BR PI0612833 A2 BRPI0612833 A2 BR PI0612833A2 BR PI0612833 A BRPI0612833 A BR PI0612833A BR PI0612833 A2 BRPI0612833 A2 BR PI0612833A2
Authority
BR
Brazil
Prior art keywords
vaccine
wing
pharmaceutical composition
arg
immunogenic
Prior art date
Application number
BRPI0612833-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Claus Aagaard
Carina Vingsbo-Lundberg
Peter Andersen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of BRPI0612833A2 publication Critical patent/BRPI0612833A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0612833-5A 2005-06-23 2006-06-20 composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras BRPI0612833A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500924 2005-06-23
DKPA200500924 2005-06-23
DKPA200501393 2005-10-05
DKPA200501393 2005-10-05
PCT/DK2006/000356 WO2006136162A2 (en) 2005-06-23 2006-06-20 Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Publications (1)

Publication Number Publication Date
BRPI0612833A2 true BRPI0612833A2 (pt) 2010-11-30

Family

ID=37134239

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612833-5A BRPI0612833A2 (pt) 2005-06-23 2006-06-20 composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras

Country Status (12)

Country Link
US (4) US7968105B2 (cg-RX-API-DMAC7.html)
EP (4) EP1910409A2 (cg-RX-API-DMAC7.html)
JP (2) JP5219808B2 (cg-RX-API-DMAC7.html)
KR (2) KR101035053B1 (cg-RX-API-DMAC7.html)
CN (1) CN102836425B (cg-RX-API-DMAC7.html)
AU (1) AU2006261445B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0612833A2 (cg-RX-API-DMAC7.html)
CA (2) CA2836319A1 (cg-RX-API-DMAC7.html)
ES (1) ES2647070T3 (cg-RX-API-DMAC7.html)
IL (3) IL188222A (cg-RX-API-DMAC7.html)
MX (1) MX2007016165A (cg-RX-API-DMAC7.html)
WO (1) WO2006136162A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529931C1 (de) 1995-08-02 1997-04-03 Mannesmann Ag Plattenkokille zur Erzeugung von Strängen aus Stahl
AU2003242504A1 (en) * 2002-07-13 2004-02-02 Statens Serum Institut Therapeutic tuberculosis vaccines
PL2136836T3 (pl) * 2007-04-04 2017-07-31 Infectious Disease Research Institute Kompozycje immunogenne zawierające polipeptydy prątka gruźlicy i produkty ich fuzji
WO2008128065A2 (en) * 2007-04-12 2008-10-23 Jennifer Lighter Tuberculosis vaccine and method of using same
US8563009B2 (en) * 2007-06-29 2013-10-22 Statens Serum Institut Use of monomycolyl glycerol (MMG) as an adjuvant
EP2244720A4 (en) * 2008-01-11 2013-01-16 Us Gov Health & Human Serv POLYPEPTIDE VACCINE AND VACCINE STRATEGY AGAINST MYCOBACTERIUM
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
HUE031044T2 (en) * 2008-07-25 2017-06-28 Glaxosmithkline Biologicals Sa Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis
ES2588183T3 (es) * 2009-03-31 2016-10-31 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal
CN102413837B (zh) * 2009-04-24 2015-11-25 国立血清研究所 预防再激活的结核病tb疫苗
CN106421743A (zh) * 2009-07-29 2017-02-22 贝恩德·赫尔穆特·阿达姆·雷姆 聚合物微粒及其用途
SG11201500171YA (en) 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
RU2520737C1 (ru) * 2013-04-25 2014-06-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА pESAT6-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-DBD, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК ESAT6-DBD И ИХ ПРИМЕНЕНИЕ
RU2539026C1 (ru) * 2013-06-11 2015-01-10 Федеральное государственное бюджетное учреждение "Центральный научно-исследовательский институт туберкулеза" Российской академии медицинских наук РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-CFP10-DBD, РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], СПОСОБ ПОЛУЧЕНИЯ, ИММОБИЛИЗАЦИИ, КОНЦЕНТРИРОВАНИЯ И ОЧИСТКИ РЕКОМБИНАНТНОГО БЕЛКА ESAT6-CFP10-DBD НА ДЕКСТРАНЕ, РЕКОМБИНАНТНЫЙ БЕЛОК ESAT6-CFP10-DBD И ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК ESAT6-CFP10-DBD
WO2014210018A1 (en) 2013-06-25 2014-12-31 Aeras Global Tb Vaccine Foundation Tuberculosis compositions and methods of using the same
CN106103471B (zh) * 2014-01-09 2020-01-07 特兰斯吉恩股份有限公司 异源寡聚分枝杆菌抗原的融合
WO2017218867A1 (en) * 2016-06-16 2017-12-21 Aeras Tuberculosis compositions and methods of treating or preventing tuberculosis
CN107970444B (zh) * 2016-10-25 2022-03-01 中国人民解放军第三0九医院 复合佐剂及含有该复合佐剂的疫苗
PH12021553146A1 (en) * 2019-06-14 2024-04-22 Statens Seruminstitut Fusion proteins for tuberculosis vaccines
EP4217066A4 (en) * 2020-09-23 2024-10-23 The General Hospital Corporation BCG VACCINES TO PREVENT COVID-19 AND OTHER INFECTIOUS DISEASES
KR102709729B1 (ko) * 2020-12-04 2024-09-25 주식회사 제넥신 결핵의 예방 또는 치료용 약학적 조성물
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
KR20240153581A (ko) 2022-02-21 2024-10-23 스태튼스 세룸 인스티튜트 신규한 양이온 어주번트 조성물
CN117531001A (zh) * 2023-11-15 2024-02-09 首都医科大学附属北京胸科医院 结核分枝杆菌毒素抗毒素系统及其相关应用
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1331C (da) 1897-11-15 Hans Daae Militær- og Skilygte.
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
WO1996009320A1 (fr) * 1994-09-20 1996-03-28 Hitachi Chemical Company, Ltd. Polypeptide antigenique de chlamydia pneumoniae
EP1741718A3 (en) 1995-06-07 2007-03-28 Sanofi Pasteur Inc. Expression of lipoproteins
US20040018574A1 (en) * 1998-08-25 2004-01-29 Marcel Behr Molecular differences between species of the M. tuberculosis complex
JP2003510326A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション アミノ置換ピラゾロ[1,5−a]−1,5−ピリミジン類及びピラゾロ[1,5−a]−1,3,5−トリアジン類
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
AU2001271963A1 (en) 2000-07-10 2002-01-21 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
JP2005522980A (ja) * 2001-04-23 2005-08-04 エリトラ ファーマシューティカルズ,インコーポレイテッド アスペルギルス・フミガーツス(Aspergillusfumigatus)の必須遺伝子の同定および使用方法
EP1404706A2 (en) * 2001-07-04 2004-04-07 Health Protection Agency Mycobacterial antigens expressed during latency
AU2003242504A1 (en) * 2002-07-13 2004-02-02 Statens Serum Institut Therapeutic tuberculosis vaccines

Also Published As

Publication number Publication date
EP2380589A3 (en) 2012-09-12
IL188222A (en) 2015-11-30
AU2006261445B2 (en) 2011-03-31
CA2836319A1 (en) 2006-12-28
CN102836425B (zh) 2015-08-19
JP5219808B2 (ja) 2013-06-26
CA2612900C (en) 2016-08-09
US20110206713A1 (en) 2011-08-25
EP2380590A3 (en) 2012-08-22
IL188222A0 (en) 2008-03-20
HK1179855A1 (zh) 2013-10-11
EP2380590A2 (en) 2011-10-26
KR20100122130A (ko) 2010-11-19
EP2163255A1 (en) 2010-03-17
US8101193B2 (en) 2012-01-24
KR20080027877A (ko) 2008-03-28
AU2006261445A1 (en) 2006-12-28
CA2612900A1 (en) 2006-12-28
CN102836425A (zh) 2012-12-26
US20090186048A1 (en) 2009-07-23
US8293250B2 (en) 2012-10-23
US7968105B2 (en) 2011-06-28
EP2163255B1 (en) 2017-08-09
MX2007016165A (es) 2008-03-14
WO2006136162A2 (en) 2006-12-28
JP2013121959A (ja) 2013-06-20
US20120114687A1 (en) 2012-05-10
EP1910409A2 (en) 2008-04-16
KR101035053B1 (ko) 2011-05-19
WO2006136162A3 (en) 2007-11-15
IL222915A0 (en) 2012-12-31
ES2647070T3 (es) 2017-12-19
JP2008543890A (ja) 2008-12-04
US8703151B2 (en) 2014-04-22
HK1124071A1 (en) 2009-07-03
IL222914A0 (en) 2012-12-31
KR101188045B1 (ko) 2012-10-05
EP2380589A2 (en) 2011-10-26
US20130095132A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
BRPI0612833A2 (pt) composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras
CN102413837B (zh) 预防再激活的结核病tb疫苗
WO2005061534A2 (en) Improved tuberculosis vaccines
CN101248084B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
AU2011203012A1 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
CIPO Prophylactic GP studies
HK1124071B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1179855B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1166018B (en) A tuberculosis tb vaccine to prevent reactivation

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2624 DE 20/04/2021.